August 5, 2024 Expanding Access to Semaglutide through 28 U.S.C. § 1498 to authorize generic competitors for semaglutide, sold by Novo Nordisk under the brand names Ozempic and Wegovy. [10] Chintan Dave, Abraham Hartzema, & Aaron Kesselheim, Prices of Generic Drugs Associated with Numbers of Manufacturers, 377 New Eng. [19] Novo Nordisk, Form 20-F (2024), Ex. 15.1: The Registrant’s Annual Report for the fiscal year ended December 31, 2023, at 51-52; Novo Nordisk, Form 20-F (2021), Ex.

Source: New York Times August 05, 2024 15:53 UTC